Robert Brannigan is an Urologist in Chicago, Illinois. Brannigan has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in Orchiectomy. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Infertility, Varicocele, Testicular Failure, Vasectomy, and Orchiectomy. He is licensed to treat patients in Illinois. Brannigan is currently accepting new patients.
Nicholas Cost is an Urologist and a Pediatrics expert in Aurora, Colorado. Cost has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in Orchiectomy. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Wilms Tumor, Testicular Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Endoscopy. He is licensed to treat patients in Colorado and Texas. Cost is currently accepting new patients.
Lawrence Einhorn is an Oncologist and a Hematologist Oncology expert in Indianapolis, Indiana. Einhorn has been practicing medicine for over 55 years and is rated as an Elite expert by MediFind in Orchiectomy. He is also highly rated in 23 other conditions, according to our data. His top areas of expertise are Testicular Cancer, Malignant Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Orchiectomy, and Bone Marrow Transplant. He is licensed to treat patients in Indiana. Einhorn is currently accepting new patients.
Summary: The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival. The researchers want to learn how long it takes for the cancer to get worse (also known as progression-free survival) by either increasing symptoms, new...
Summary: The purpose of this study is to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study will be conducted in two phases: Double-Blind treatment phase and open-label phase.